Posted on April 27, 2020 by Sitemaster
According to a media release issued by AstraZeneca and Merck on Friday evening, olaparib (Lynparza) has shown “a statistically significant and clinically meaningful improvement in … overall survival (OS)” in men with metastatic, castration-resistant prostate cancer (mCRPC) and BRCA1/2 or ATM gene mutations (homologous repair gene mutations or HRRm). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: gene, Lynparza, mCRPC, mutation, olaparib, Profound, repair | 11 Comments »
Posted on October 1, 2019 by Sitemaster
From a report presented by Hussain yesterday at the annual meeting of the European Society for Medical Oncology (ESMO) we gained detailed insight into the results of the PROfound trial of olaparib (Lynparza), which had been said to be positive last August. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, gene, Lynparza, mCRPC, metastatic, mutation, olaparib | 3 Comments »
Posted on October 8, 2018 by Sitemaster
A newly published paper in the journal Prostate Cancer and Prostatic Diseases has explored the above question based on data from the Johns Hopkins active surveillance (AS) cohort of men with initially low- or very low-risk prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, association, enzyme, gene, PTEN, surveillance | 4 Comments »
Posted on January 10, 2018 by Sitemaster
Data from the ongoing, prospective IMPACT study has shown that PSA velocity is not predictive of risk for a positive prostate cancer biopsy result in men who are carriers of the BRCA2 gene. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: BRCA1/2, gene, hereditary, PSA, risk, status, velocity | 1 Comment »
Posted on September 22, 2017 by Sitemaster
A new paper by an international group of researchers from several different centers has maybe identified a new way to differentiate accurately between indolent and aggressive forms of prostate cancer at time of initial diagnosis. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: aggressive, expression, EZH2, gene, indolent, risk, TOP2A | 1 Comment »
Posted on August 30, 2017 by Sitemaster
Within the past few hours, the US Food and Drug Administration (FDA) has approved the very first form of chimeric antigen receptor (CAR) T-cell therapy for the treatment of cancer — and this is also the first true form of gene therapy to be made available here in the US. … READ MORE …
Filed under: Uncategorized | Tagged: CAR-T, CTL019, gene, Kymriah, therapy, tisagenlecleucel | 2 Comments »
Posted on August 9, 2017 by Sitemaster
A newly published and very detailed paper based on data from the PRACTICAL consortium now seems to have confirmed that taller men are at greater risk for high-risk prostate cancer than shorter ones (like your sitemaster). … READ MORE …
Filed under: Diagnosis, Risk | Tagged: gene, grade, growth, Height, risk | 1 Comment »
Posted on May 5, 2017 by Sitemaster
A group at The Institute for Cancer Research and The Royal Marsden Hospital in the UK — along with other European colleagues — has come up with a new, relatively low-cost test that seems to be able to identify men with advanced forms of prostate cancer who are more or less likely to respond well to treatment with drugs like abirateone acetate and enzalutamide. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen, gene, receptor, resistance, test | 4 Comments »
Posted on August 29, 2016 by Sitemaster
According to an article to appear in the September issue of The Lancet Oncology, some patients with aggressive prostate cancer are more likely to die earlier from their disease if they carry a specific testosterone-related genetic abnormality. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, aggressive, gene, HSD3BI, LESS, responsive | 2 Comments »
Posted on August 4, 2016 by Sitemaster
A new study in this week’s New England Journal of Medicine reports that DNA-repair germline mutations were found in nearly 12 percent of patients who had metastatic prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: DNA, gene, germline, metastatic, mutation, repair, risk | 6 Comments »
Posted on March 21, 2016 by Sitemaster
Drugs like docetaxel and cabazitaxel (taxanes) are among the most active forms of treatment in the management of men with metastatic, castration-resistant prostate cancer (mCRPC), but they don’t work for everyone. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Risk, Treatment | Tagged: cabazitaxel, docetaxel, expression, gene, taxane, TMPRSS2-ERG | Leave a comment »
Posted on December 28, 2015 by Sitemaster
A newly published article in the journal PLoS One questions whether the Decipher® test (a 22-gene expression assay test) has actual clinical utility in helping physicians to make good decisions about the follow-up treatment of men with prostate cancer after an initial radical prostatectomy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: assay, Decipher, gene, metastasis, risk | Leave a comment »
Posted on December 14, 2015 by Sitemaster
A report in the Journal of Radiation Oncology is making big claims for the effectiveness of a combination of intensity-modulated radiation therapy (IMRT) along with “suicide gene” therapy as first-line treatment for localized prostate cancer … but there are some real questions that need real answers. … READ MORE …
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: ADV/HSV-tk, gene, localized, suicide | 2 Comments »
Posted on December 10, 2015 by Sitemaster
A recent article in the International Journal of Cancer lays out a possible future scenario for prostate cancer risk assessment that takes specific account of familial and hereditary risks for clinically significant prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: allele, Diagnosis, gene, heredity, market, mutation, risk | Leave a comment »
Posted on October 13, 2015 by Sitemaster
According to an hypothesis just published by a group of researchers at the Dana-Farber Cancer Institute in Boston, they have identified “a new epigenetic program occurring as you transition from normal to tumor cells” in the development of prostate cancer. … READ MORE …
Filed under: Risk | Tagged: cancer, development, epigenetics, gene, programming, prostate | Leave a comment »
